Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-02-2002
Volume 26
Issue 3

Public CROs are creating new ways of operating their outsourcing businesses to remain competitive in difficult economic conditions.

External Link - article-12403.pdf

Articles in this issue
Outsourcing Outlook
Developing Custom Adhesive Systems for Transdermal Drug Delivery
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part II
PDA Task Force Issues Guidelines to Aid Isolator Users
Recent Advances in Semisolid Dosage Forms for Dermatological Application
Drug Safety Concerns Shape Manufacturing Policy
Production Information Mangement
Functionality Testing of a Multifunctional Directly Compressible Adjuvant Containing Lactose, Polyvinylpyrrolidone, and Croscarmellose Sodium
Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives
Validation Changes to the USP Assay Method for Ibuprofen Tablets
Systematic Troubleshooting for LC/MS/MS
Product Development Issues of Powders for Injection
Oral Low Molecular Weight Heparin Absorption From Solution and Solid Dosage Forms in Rat, Dog, and Monkey Models
Pharmaceutical Reserch and Manufacturers Association Acceptable Analytical Practice for Analytical Method Transfer
Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Drug Digest: Strategic Partnerships
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New CDMO Meribel Pharma Solutions Launches with 13 Sites in Europe

Patrick Lavery
April 16th 2025
Article

The new United Kingdom-based firm has sites located in France, Spain, and Sweden, thanks to an acquisition of Synerlab Group and several Recipharm facilities in 2024.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Patrick Lavery
April 8th 2025
Article

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 2nd 2023
Podcast

In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

drug manufacturing

Pharma 4.0: What are Industry Leaders Prioritizing in the Modernization of Pharmaceutical Manufacturing?

Alicia Bigica
April 3rd 2025
Article

The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing.

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.